Stockscreener 앱 받기
2.3653
7.39%
-0.2047
전일 마감가:
$2.57
열려 있는:
$2.45
하루 거래량:
18,082
Relative Volume:
15.60
시가총액:
$20.86M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.34
$2.47
1주일 범위
$2.33
$2.65
52주 변동 폭
$2.33
$2.65
Metavia Inc Stock (MTVA) Company Profile
MTVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
2.3645 | 20.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.94 | 117.11B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.18 | 82.10B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.11 | 36.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.69 | 32.56B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.19 | 27.71B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metavia Inc 주식(MTVA)의 최신 뉴스
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
MTVAMTVA Latest Stock News & Market Updates - StockTitan
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors - Marketscreener.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Da-1726 Effectively Reduces Body Weight and Glycemic Control Data At the American Diabetes Association's 83Rd Scientific Sessions - Marketscreener.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces CEO Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces the Appointment of Current Board Member, Hyung Heon ("H.H.") Kim as the Company's President, Principal Executive Officer, and Principal Accounting Officer - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo Pharmaceuticals Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Exclusive License Agreement with MThera Pharma Co., Ltd. for NB-01 - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Elects Hyung Heon Kim and Andrew I. Koven to Board of Directors - Marketscreener.com
NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments - TipRanks
NeuroBo Pharmaceuticals changes name to MetaVia - KBR
NeuroBo Pharmaceuticals rebrands to become MetaVia - FiercePharma
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
Finansavisen - Finansavisen
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are BuyingMetaVia (NASDAQ:NRBO) - Benzinga
Quest Store Revenue Reaches $2 Billion, But Momentum Has Slowed Over the Last Year - Road to VR
NeuroBo Pharmaceuticals : Company Presentation January 2021 - Marketscreener.com
Metavia Inc (MTVA) 재무 분석
Metavia Inc (MTVA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.29%
2.28%
자본화:
|
볼륨(24시간):